MMR Information Systems
Latest From MMR Information Systems
Biovest International's (Accentia Biopharmaceuticals) therapeutic cancer vaccine BiovaxID looks to have become the first to improve disease-free survival (DFS) in follicular lymphoma (FL) in the pivotal Phase III BV-301 study that was highlighted at a plenary session at the ASCO meeting in Orlando.
Favrillehas resolved its debt obligation to its creditors, General Electric Capital Corporation and Oxford Financial Corporation, which have agreed to release the general lien on the company's assets. The lenders have now received $8.8 million as repayment of outstanding principal and accrued interest and Favrille has reimbursed them with $47,000 of further transaction costs. Acceleration of the loan was triggered after the company's cash fell below the $14.5 million minimum cash covenant on May 30th. Following the failure of the company's lead product, Specifid, to demonstrate activity in a Phase III registration trial, Favrille's future looks uncertain. The company now faces either a reorganisation which might involve in-licensing of products, a merger with another entity or liquidation of the company either inside or outside of bankruptcy, said Dr John Longenecker, president and CEO of Favrille.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.